“When you can’t breathe, nothing else matters.”
That’s the position of Sharon Samjitsingh, co-founder and CEO of a fast-growing health tech company called Health Care Originals (HCO).
HCO is on a mission to revolutionize the eighty-three-billion-dollar respiratory-care market. It’s created an Artificial Intelligence-powered virtual respiratory-care platform that is bringing continuous, personalized care for the 690 million sufferers of asthma and chronic obstructive pulmonary disease (COPD) — the third-leading cause of death globally.
Every day in the U.S., there are 30,000 asthma attacks, 15,600 COPD office visits, and 430 respiratory-related deaths.
Chronic respiratory conditions affect people of all ages. And those living with these conditions struggle with daily tasks as flare-ups lead to heightened anxiety, panic, and frequent hospital visits. Forty-seven billion dollars in avoidable costs are spent each year on related hospital and doctor’s visits associated with respiratory conditions.
Medication isn’t always effective for these people. Neither is a one-size-fits-all approach to healthcare. What’s the solution?
HCO has created a virtual platform and smart wearable that offers unique insights and actionable data, enabling wearers to take control of their respiratory care. Here’s how it works:
Users wear an undetectable device that is attached to the body. This device continuously tracks and analyzes respiratory health by listening to deep organ sounds — the first company in the world to take this approach — and these sounds create important digital biomarkers.
Users are alerted to predictive and actionable insights to prevent flare-ups, while respiratory therapists and health coaches monitor the data and offer ongoing support.
HCO has achieved notable efficacy. Within six months, 100% of users reported reduced wheezing and shortness of breath. Ninety percent reported improved sleep and sixty-seven percent experienced no attacks at all.
HCO is backed by venture-capital funds Safar Partners and Chloe Capital. And it has signed contracts valued at $5.5 million in projected annual-recurring revenue, based on recruiting just four percent of the total customers available to the company. The company has a wait list of more than 12,000 potential users.
HCO projects to surpass five million dollars in revenue this year and thirty-four million dollars in revenue in 2026.
HCO’s profit potential is notable. Similar health tech companies have transitioned care from high-cost medical interventions such as surgeons and clinical visits to more scalable expert care delivered through digital channels. And many have become multi-billion-dollar businesses as a result.
Furthermore, recent strategic acquisitions of health devices highlight the demand for innovative solutions, such as HCO’s platform.